Abstract
We have identified eight sub-dimensions of patient access to pharmaceuticals: marketing approvals, time of marketing approval, coverage, cost sharing, conditions of reimbursement, speed from marketing approval to reimbursement, extent to which beneficiaries control choice of their drug benefit, and evenness of the availability of drugs to the population. For a sample of commonly used best-selling drugs in the United States (US), we measured these eight access sub-dimensions across four health systems: France, the Netherlands, the United Kingdom (UK), and the US. Although the US approved between 15 and 18% more drugs than the other three countries, the US was slower than France and the UK to approve drugs licensed in all four countries. The percentage of drugs covered is approximately the same for all four countries. For covered drugs, we observe the least cost sharing by patients in the Netherlands. The Netherlands imposes conditions of reimbursement on a much larger percentage of drugs. France seems to be the slowest in respect of speed from marketing approval to reimbursement. The US is the most flexible in terms of the extent to which beneficiaries control their choice of drug benefit but it is the least universal in terms of evenness of the availability of drugs to the population. Our study confirms the frequently cited problems of access in European countries: lag between marketing approval and reimbursement, and inflexibility in respect of the extent to which beneficiaries control their choice of drug benefit. At the same time, our study confirms, qualitatively, different kinds of access problems in the US: relatively high patient cost sharing for pharmaceuticals, and wide variation in coverage.
Similar content being viewed by others
Notes
Inpatient drugs may be subject to hospital budget caps.
The Omnibus Budget Reconciliation Act of 1990 requires manufacturers to pay a rebate to the Medicaid program. For brand-name drugs, the rebate is equal to the greater of 15.1% of the average price paid to a manufacturer for the drug and the difference between this price and the lowest price paid by any private-sector purchaser for the drug.
All direct federal purchasers of health care services, for example the Department of Veterans Affairs (VA), can purchase drugs at prices listed in the Federal Supply Schedule (FSS) for pharmaceuticals. The VA negotiates FSS prices with manufacturers on the basis of the prices that manufacturers charge their most-favored commercial customers. These prices are usually up to 50% off of the average wholesale price.
We filled gaps in our database of drug approvals by means of personal communications with officials at the respective drug-regulatory agencies.
Note that of the 100 drugs all four regulatory agencies approved 87 with the same active ingredient, but only 79 with the same formulation and dosing in addition to same active ingredient.
Prior authorization requires that some drugs be pre-authorized before their being dispensed to be eligible for reimbursement.
Note, the IMS database does not take into account delays because of launch delays.
Personal communication [Lucy Betteron, NICE, October 10, 2005].
References
Association for the British pharmaceutical industry 2003 report: competitive task force—competitive and performance indicators 2003. See http://www.abpi.org.uk/publications, accessed June 1, 2006
Buchmueller, T., Couffinhal, A.: Private health insurance in France. OECD Health working paper No. 12. 2004. See http://www.oecd.org/els/health/workingpapers, accessed April 5, 2006
Civitas. Are the NHS reforms working? NHS: is the extra money working? 2003. See http://www.civitas.org.uk/nhs/nhsmoney.php, accessed April 2, 2006
Cohen, J., Paquette, C., Cairns, C., Faden, L.: Comparing UK and US pharmacoeconomic assessments: case study of 38 NICE technology appraisals. Appl. Health Econ. Health Policy 5(3), 1–11 (2006)
Colombo, F., Tapay, N.: Private health insurance in OECD countries: the benefits and costs for individuals and health systems. OECD working paper 2005. See http://www.oecd.org/dataoecd/34/56/33698043.pdf, accessed March 10, 2006
Danzon, P.: Welfare effects of supplementary insurance: a comment. J. Health Econ. 21, 923–926 (2002)
Danzon, P., Ketcham, J.: Reference pricing of pharmaceuticals for medicare: evidence from Germany, the Netherlands, and New Zealand. NBER working paper series. See http://www.nber.org/papers/w1007, accessed March 7, 2006
Danzon, P., Wang, R., Wang, L.: The impact of price regulation on the launch delay of new drugs—evidence from 25 major markets in the 1990s. Health Econ. 14, 269–292 (2005)
Docteur, E., Oxley, H.: health-care systems: lessons from the reform experience. OECD working paper 2005. See http://www.oecd.org/dataoecd/5/53/22364122.pdf, accessed on march 10, 2006
Drug topics: top brand-name drugs by retail sales in 2005. See http://www.drugtopics.com/drugtopics/article/articleDetail.jsp?id=104561, accessed on April 1, 2006
Fox, P.: Prescription drug benefits: cost management issues for Medicare. See http://www.cms.hhs.gov/apps/review/03_04winter/03_04winterpg7.pdf, accessed on April 5, 2006
Heffler, S., Smith, S., Keehan, S., Borger, C., Clemens, M., Truffer, C.: Trends: US health spending projections for 2004–2014. Health Affairs 2005 web exclusive. See http://content.healthaffairs. org/content/vol0/issue2005/images/data/hlthaff.w5.74/DC1/Heffler05_E.5. gif, accessed on April 19, 2006
Hoadley, J., Hargrave, E., Cubanski, J., Neuman, T.: An in-depth examination of formularies and other features of Medicare drug plans. See http://www.kff.org/medicare/7489.cfm, accessed on May 29, 2006
Hoadley, J.: Cost containment strategies for prescription drugs – assessing the evidence in the literature, March 2005, http://www.kff.org, accessed on January 12, 2006
Hurwitz, B.: Legal and political considerations of clinical practice guidelines. BMJ 318, 661–664 (1999)
Jonsson, B., Wilking, N.: A pan-European comparison of patient access to cancer medications. See http://ki.se/content/1/c4/33/52/Cancer_Report.pdf, accessed on April 4, 2006
Lancry, P., et al.: Using health outcomes data to inform decision-making: healthcare payer perspective. Pharmacoeconomics 19(2), 39–47 (2001)
Le Pen, C.: Drug pricing and reimbursement in France: towards a new model? Pharmacoeconomics 10(Suppl. 3), 26–36 (1996)
Mossialos, E., Walley, T., Mrazek, M. (eds.) Regulating pharmaceuticals in Europe: an overview, striving for efficiency, equity, and quality. Open University Press, London (2004)
Neumann, P.: Why don’t Americans use cost-effectiveness analysis. Am. J. Manag. Care 10(5), 308–312 (2004)
OECD Health Data 2005. See http://www.oecd.org, accessed on May 21, 2006
PDUFA, FDA and stakeholders public meeting. See http://www.fda.gov/ohrms/dockets/05n0410/05n-0410-tr0001-vol2.pdf, accessed on March 24, 2006
Prescription drug coverage, spending, utilization, and prices. See http://www.aspe.hhs.gov, accessed on November 29, 2005
Pronk, M., Bonsel, G.: De budgetbeheersende functie van het geneesmiddelenvergoedingssysteem, 10 jaar GVS. Nederlands Tijdschrift voor de Geneeskunde. 146(37) (2002)
Rodwin, V., Sandier, S.: Health care under French national health insurance. See http://www.nyu.edu/projects/rodwin/french.html, accessed on January 11, 2006
Ryan, M.: Discrete choice experiments in health care. BMJ 328, 382 (2004)
See http://www.drugtopics.com/drugtopics/data/articlestandard/drugtopics/082006/309440/article.pdf, accessed on November 29, 2005
See http://www.cbg-meb.nl, accessed on March 1, 2006
See http://www.cbo.nl/home_html, accessed on June 1, 2006
See http://www.euro.who.int/Document/Obs/EuroObserver6_3.pdf, accessed on March 10, 2006
See http://www.irpp.org/events/archive/sep02/willison.pdf, accessed on March 25, 2006
See http://www.has-sante.fr, accessed on March 11, 2006
See http://afssaps-prd.afssaps.fr/html/has/sgt/htm/smr/indsmr.htm, accessed April on 19, 2006
See http://europa.eu.int/comm/enterprise/phabiocom/docs/tse/usa.pdf, accessed on March 25, 2006
See http://www.pbmi.com, accessed on January 31, 2006
See http://www.cbo.gov/ftpdocs/64xx/doc6481/06-16-PrescriptDrug.pdf, accessed on March 8, 2006
See http://www.amcp.org, accessed on March 10, 2006
See http://www.fda.gov, accessed on January 15, 2006
See http://www.mhra.gov.uk, accessed on February 23, 2006
See http://www.cbg-meb.nl, accessed on April 2, 2006
See http://www.afssaps.fr, accessed on March 3, 2006
See https://online.epocrates.com, accessed on May 31, 2006
See http://www.cvz.nl, accessed on March 1, 2006
See https://online.epocrates.com, accessed on May 29, 2006
See http://www.nice.org.uk, accessed on March 1, 2006
See http://www.has-sante.fr, accessed on March 23, 2006
See http://www.cms.hhs.gov/CapMarketUpdates/Downloads/hcimu120503.pdf, accessed on April 3, 2006
See http://www.pbmi.com, accessed on June 15, 2006
See http://www.fda.gov/oc/speeches/2003/eufeps1208.html, accessed on April 19, 2006
See http://www.who.int/intellectualproperty/studies/Lanjouw_Price&LaunchFinal.pdf, accessed on April 5, 2006
Stolk, E., Brouwer, W., Busschbach, J.: Rationalizing rationing: economic and other considerations in the debate about funding of Viagra. Health Policy 59(1), 53–63 (2002)
Syrett, K.: A technocratic fix to the “legitimacy problem”? The Blair Government and Health Care Rationing in the United Kingdom. J. Health Polit. Policy Law 28, 715–746 (2003)
Ten leading nationwide 3-tier formularies, in terms of enrollment. See http://www.aishealth.com, accessed May on 23, 2006
Towse, A.: The efficient use of pharmaceuticals: does Europe have any lessons for a Medicare drug benefit? Health Aff. 22(3), 42–45 (2003)
Varkevisser, M., van der Geest, S.: “Price Competition Among Dutch Sickness Funds”, Erasmus University Research Centre For Economic Policy Research Memorandum 0112, (2001). See http://www.ocfeb.nl, accessed on March 7, 2006
Whalen, J.: Britain stirs outcry by weighing benefits of drugs versus price. The Wall Street Journal, November 22, 2005
Author information
Authors and Affiliations
Corresponding author
Appendix
Appendix
Table 7
Rights and permissions
About this article
Cite this article
Cohen, J., Faden, L., Predaris, S. et al. Patient access to pharmaceuticals: an international comparison. Eur J Health Econ 8, 253–266 (2007). https://doi.org/10.1007/s10198-006-0028-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10198-006-0028-z